Targeting the Adenosine Pathway for Enhancing Cancer Therapy

Grant number: 1062580 | Funding period: 2014 - 2016

Completed

Abstract

We have shown that drugs that block immunosuppressive adenosine receptors can improve anti-tumour immune responses and consequently enhance the effectiveness of chemotherapy. These drugs are already known to be well-tolerated in humans and so have great potential for clinical development. We propose to determine the therapeutic response achieved with these drugs in combination with established cancer treatments involving radiotherapy and immune based therapies.

Related publications (6)

Scholarly works icon

Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity

J Lai, S Mardiana, IG House, K Sek, MA Henderson, L Giuffrida, AXY Chen, KL Todd, EV Petley, JD Chan, EM Carrington, AM Lew, BJ Solomon, JA Trapani, K Kedzierska, M Evrard, SJ Vervoort, J Waithman, PK Darcy, PA Beavis

2020-08-01

Adoptive cell therapies using genetically engineered T cell receptor or chimeric antigen receptor T cells are emerging forms of im..

Scholarly works icon

Switching on the green light for chimeric antigen receptor T-cell therapy

S Mardiana, J Lai, IG House, PA Beavis, PK Darcy

2019-01-01

Adoptive cellular therapy involving genetic modification of T cells with chimeric antigen receptor (CAR) transgene offers a promis..

Scholarly works icon

Dual PD-1 and CTLA-4 Checkpoint blockade promotes antitumor immune responses through CD4 þ FOXP3 – cell–mediated modulation of CD103 þ dendritic cells

PA Beavis, MA Henderson, L Giuffrida, AJ Davenport, EV Petley, IG House, J Lai, K Sek, N Milenkovski, LB John, S Mardiana, CY Slaney, JA Trapani, S Loi, MH Kershaw, NM Haynes, PK Darcy

2018-09-01

Immunotherapy is widely accepted as a powerful new treatment modality for the treatment of cancer. The most successful form of imm..

Scholarly works icon

A multifunctional role for adjuvant anti-4-1BB therapy in augmenting antitumor response by chimeric antigen receptor T cells

S Mardiana, LB John, MA Henderson, CY Slaney, B Von Scheidt, L Giuffrida, AJ Davenport, JA Trapani, PJ Neeson, S Loi, NM Haynes, MH Kershaw, PA Beavis, PK Darcy

2017-03-15

Adoptive immunotherapy utilizing chimeric antigen receptor (CAR) T cells has demonstrated high success rates in hematologic cancer..

Scholarly works icon

Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy

PA Beavis, MA Henderson, L Giuffrida, JK Mills, K Sek, RS Cross, AJ Davenport, LB John, S Mardiana, CY Slaney, RW Johnstone, JA Trapani, J Stagg, S Loi, L Kats, D Gyorki, MH Kershaw, PK Darcy

2017-03-01

Chimeric antigen receptor (CAR) T cells have been highly successful in treating hematological malignancies, including acute and ch..

Scholarly works icon

CD73: A potential biomarker for anti-PD-1 therapy

PA Beavis, CY Slaney, N Milenkovski, MA Henderson, S Loi, J Stagg, MH Kershaw, PK Darcy

2015-11-02

In our recent study, we show that tumoral CD73 expression limits the efficacy of anti-PD-1 therapy, and this is rescued by concomi..

University of Melbourne Researchers